Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Joseph Strohsahl who wrote (1373)	6/3/1999 3:32:00 PM
From: Bob Walsh	Respond to of 1510

HIV-VAC To Investigate IMNR's HIV Vaccine Setback TORONTO, ONTARIO (June 3) BUSINESS WIRE -June 3, 1999--HIV-VAC, Inc, (OTC BB:HIVC) announced today that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, the developer of HIV-VAC's HIV vaccine has expressed interest in Immune Response Corp's (NASDAQ:IMNR) Remune HIV vaccine tests that have ended due to their minimal effect when added to conventional anti-HIV "cocktail" therapies. "I am very interested in examining Immune Response Corp.'s conclusion of their Phase III HIV vaccine trials. This was done on the recommendation of an Independent Data Safety Monitoring Board (DSMB)," Dr. Skinner said. "We will be requesting detailed, unprocessed information on these trials from the DSMB to help us further our development of our HIV-VAC vaccine which will begin clinical trials within six to nine months." HIV-VAC's HIV vaccine was developed by Dr. Skinner at the University of Birmingham, United Kingdom. It has been under development for the last 10 years. Toxicity trials are almost completed. Dr. Skinner added, "The HIV-VAC vaccine is expected to prevent the disease, and also may prevent the onset of AIDS in HIV-positive patients. Many scientists have been working on a vaccine for AIDS over the last 10 years. We have developed a new approach to the AIDS problem through the creation of an intracellular vaccine based on technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines." The HIV-VAC patented intracellular vaccine approach includes gp120/160 and uses core proteins p55, p24, p17 and others. The multi-protein approach used by HIV-VAC covers the whole spectrum of HIV virus proteins and is believed to offer a rational approach both as a vaccine and for therapeutic purposes. Because the HIV-VAC vaccine proteins are harvested from virus particles and from intracellular virus-coded proteins, the entire spectrum of virus proteins is available for presentation to the immune system. The United Nations estimates that there are currently 30.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million. The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here. -0- mj/ny* nmb CONTACT: HIV-VAC, Toronto K. Jelsing, Investor Relations 877/778-7731 or For Live Interview: www.wallstreetinterview.com KEYWORD: INTERNATIONAL CANADA INDUSTRY KEYWORD: MEDICINE Today's News On The Net - Business Wire's full file on the Internet